Self-Supervised Constraint-Induced Movement Therapy for Stroke Recovery

This study is testing a therapy called Self-Supervised Constraint-Induced Movement Therapy (sCIMT) for adults who have weakness in their arm and hand after a stroke. The goal is to see if this program can help people use their affected arm and hand better, while also requiring less time with a therapist. Researchers will also check if participants find the program useful and if it improves their daily well-being. You might be able to join if you are 18-85 years old, had your first stroke at least two weeks ago, and have moderate arm weakness. The study aims to enroll 12 participants, but its current recruitment status is unclear.

Study design: This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 12 participants, but the phase of the study is not specified.
What's involved: Participants will take part in a therapy program five times a week for two weeks. Each session will last three hours.
Compensation: Not stated in the trial record.
Follow-up: Researchers will measure your arm movement and how you use the therapy within one week after you complete the two-week program.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Self-Supervised Constraint-Induced Movement Therapy for Stroke Recovery

Recruiting

NAAges 18–85InterventionalTreatment

Ohio State University

~12 participants

Updated 2026-08-25 on ClinicalTrials.gov

What's tested:Self-Supervised Constraint-Induced Movement Therapy (sCIMT)

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Change in Action Research Arm Test (ARAT) Score from Baseline to Post-Intervention

Measured over Baseline and post-intervention (within 1 week of completing the 2-week sCIMT program)

+1 more outcome measured

Conditions

Stroke

Stroke (CVA) or TIA

Cerebral Vascular Accident (CVA)/Stroke

NCT07723300

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Ohio State University
Columbus, Ohiono site contact published
Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Peyton Miller

[email protected]

380-283-5825

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Sustained a first-time ischemic or hemorrhagic stroke ≥2 weeks prior to study enrollment

Age ≥18 and ≤85

Moderate UE hemiparesis as defined by a score ≥13 and ≤47 on the modified UE section of the Fugl-Meyer Assessment (60-point scale with no reflex testing)

Ability to actively extend impaired wrist ≥10 degrees

UE strength and active range of motion within functional limits on the non-hemiparetic side

Ability to follow two-step commands (visual or verbal) as determined by the clinical investigator

Nonuse of the more impaired UE as evidenced by an average score ≤2.5 on the Motor Activity Log Amount of Use Scale.

Exclusion

Excessive pain in the affected shoulder, arm, or hand as measured by a score ≥6 on a 10-point visual analogue scale

Unable to passively reach neutral position for wrist extension and forearm supination

Excessive spasticity in the affected wrist or finger flexors/extensors and elbow flexors, as defined as a score of \>2 on the Modified Ashworth Scale (MAS)

Inability to actively participate in regular therapy sessions (e.g., due to medical complexity, insufficient endurance, transportation, etc.) as determined by participant or by clinical judgement of the evaluating therapist

Receiving occupational therapy services for the hemiparetic UE during the two-week intervention window (including after pre-assessment and before post-assessment)

Received focal anti-spasticity drug injection (e.g., Botox) to any muscles of the impaired UE within the past 1 month (or plan to at some point during study enrollment)

Comorbid diagnosis in addition to stroke (e.g., dementia, peripheral neuropathy) that in the opinion of the investigator could impact study results

Presence of moderate to severe unilateral spatial neglect as indicated by clinical observation or failure on a standardized screening tool (e.g., Line Bisection Test or Bells Test).

What this trial measures

Change in Action Research Arm Test (ARAT) Score from Baseline to Post-InterventionBaseline and post-intervention (within 1 week of completing the 2-week sCIMT program)
The Action Research Arm Test (ARAT) will be used to assess upper extremity motor function. The ARAT is a standardized performance-based measure consisting of 19 items that evaluate grasp, grip, pinch, and gross arm movement. Total scores range from 0 to 57, with higher scores indicating better upper extremity function. The primary outcome will be the change in ARAT score from baseline (pre-intervention) to post-intervention following completion of the self-supervised constraint-induced movement therapy (sCIMT) program.
Implementation of sCIMT (AIM, FIM, IAM Score)Post-intervention (within 1 week of completing the 2-week sCIMT program)
The Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM) comprise a standardized implementation outcomes instrument that evaluates participants' perceptions of an intervention's acceptability, appropriateness, and feasibility. The instrument consists of 12 items (4 items per domain), each rated on a 5-point Likert scale, with higher scores indicating greater perceived acceptability, appropriateness, and feasibility.

Trialytics